Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems (Dual Stage Ultrafilter). The company operates primarily in European and Canadian markets for medical filters and pursues government contracts for military water purification.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Product Revenue | $1,799 | $1,158 |
| Gross Margin | $672 (37.4%) | $370 (32.0%) |
| Net Loss | $(893) | $(1,148) |
| Cash and Equivalents | $344 | $1,004 (Dec 31, 2009) |
| Net Cash Used in Operating Activities | $(719) | $(1,430) |
| Total Assets | $1,942 | $2,652 (Dec 31, 2009) |
| Total Liabilities | $867 | $694 (Dec 31, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 55% year-over-year to $1.8 million, driven by a 77% increase in unit sales of MD filters in Europe and higher sales of the Dual Stage Ultrafilter (DSU) in the U.S.
- Improved Loss Position: Net loss decreased by approximately $255,000 compared to the prior year period, primarily due to higher revenues and reduced operating expenses.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased by 5% ($64,000) due to lower personnel and marketing costs, partially offset by higher professional fees. Depreciation expense dropped 50% as several assets were fully depreciated.
- Cash Burn: While cash burn from operations improved (decreased from $1.43M to $0.72M), cash balances declined from $1.0M to $344K due to inventory buildup and receivables growth.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. Funds are projected to be depleted in the fourth quarter of 2010 without additional financing.
- Capital Needs: The company is investigating strategic funding opportunities, including a pending Form S-1 offering (as of filing date) and potential licensing deals. There is no guarantee of obtaining funds.
- Regulatory Status: The FDA issued a final decision letter on June 30, 2010, stating it could not reach a substantial equivalence determination for the company's HDF system. A meeting is scheduled for September 2010 to discuss next steps, which may include a new application or appeal. This does not affect sales outside the U.S.
- Supply Chain Risk: The exclusive fiber supplier notified the company of its intent to terminate the supply agreement effective July 18, 2010. Negotiations for a new agreement are ongoing, and the company currently holds adequate inventory.
- Management Changes: The former CEO resigned in March 2010. Paul Mieyal (Board Member) serves as Acting CEO. A separation agreement with the former CEO resulted in accrued severance of approximately $22,000.
Investor Verification Checklist
- Liquidity Runway: Verify the status of the pending Form S-1 offering and the timeline for raising capital to avoid insolvency in Q4 2010.
- FDA Resolution: Monitor the outcome of the September 2010 FDA meeting regarding the HDF system 510(k) application.
- Supply Agreement: Confirm the execution of a new supply agreement with the fiber manufacturer to ensure continuity of European sales.
- Customer Concentration: Note that two customers accounted for 86% of sales in the first half of 2010 (49% and 37%), creating significant revenue concentration risk.
- Deferred Revenue: Verify the recognition timeline for the $100,000 deferred revenue from the STERIS Corporation development agreement.